相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Inhibition of bladder cancer growth with homoharringtonine by inactivating integrin α5/β1-FAK/Src axis: A novel strategy for drug application
Qiushuang Wu et al.
PHARMACOLOGICAL RESEARCH (2023)
Identification of Homoharringtonine as a potent inhibitor of glioblastoma cell proliferation and migration
Elena Porcu et al.
TRANSLATIONAL RESEARCH (2023)
Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia
Jayastu Senapati et al.
LEUKEMIA (2023)
Integrating animal experiments, mass spectrometry and network-based approach to reveal the sleep-improving effects of Ziziphi Spinosae Semen and & gamma;-aminobutyric acid mixture
Airong Ren et al.
CHINESE MEDICINE (2023)
Caffeic acid phenethyl ester protects against doxorubicin-induced cardiotoxicity and increases chemotherapeutic efficacy by regulating the unfolded protein response
Ying Zhang et al.
FOOD AND CHEMICAL TOXICOLOGY (2022)
Mitochondrial Respiratory Chain Supercomplexes: From Structure to Function
Shuting Guan et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
B-Lymphoid Blast Phase-Chronic Myeloid Leukemia: Current Therapeutics
Binoy Yohannan et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Metabolic targeting of cancer by a ubiquinone uncompetitive inhibitor of mitochondrial complex I
Shashi Jain et al.
CELL CHEMICAL BIOLOGY (2022)
Chronic myeloid leukemia stem cells: targeting therapeutic implications
Hanieh Mojtahedi et al.
STEM CELL RESEARCH & THERAPY (2021)
Design, synthesis, and biological evaluation of Bcr-Abl PROTACs to overcome T315I mutation
Liang Jiang et al.
ACTA PHARMACEUTICA SINICA B (2021)
Identification of dihydrotanshinone I as an ERp57 inhibitor with anti-breast cancer properties via the UPR pathway
Wei Shi et al.
BIOCHEMICAL PHARMACOLOGY (2021)
Petasin potently inhibits mitochondrial complex I-based metabolism that supports tumor growth and metastasis
Kazuki Heishima et al.
JOURNAL OF CLINICAL INVESTIGATION (2021)
Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations
Xiaoyun Lu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Ponatinib and other CML Tyrosine Kinase Inhibitors in Thrombosis
Peng Zeng et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Chronic Myeloid Leukemia, Version 2.2021
Michael W. Deininger et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)
The coupling mechanism of mammalian respiratory complex I
Domen Kampjut et al.
SCIENCE (2020)
Essential role of accessory subunit LYRM6 in the mechanism of mitochondrial complex I
Etienne Galemou Yoga et al.
NATURE COMMUNICATIONS (2020)
SIRT1 regulates metabolism and leukemogenic potential in CML stem cells
Ajay Abraham et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy
Federico Rossari et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Novel biflavonoids from Cephalotaxus oliveri Mast.
Dai Ren et al.
PHYTOCHEMISTRY LETTERS (2018)
Ponatinib: A Review of Efficacy and Safety
Fulvio Massaro et al.
CURRENT CANCER DRUG TARGETS (2018)
Tyrosine Kinase Inhibitor Treatment for Newly Diagnosed Chronic Myeloid Leukemia
Jerald P. Radich et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2017)
Synthesis and identification of GZD856 as an orally bioavailable Bcr-AblT315I inhibitor overcoming acquired imatinib resistance
Xiaoyun Lu et al.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2017)
Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells
Elodie M. Kuntz et al.
NATURE MEDICINE (2017)
Homoharringtonine suppresses imatinib resistance via the Bcl-6/p53 pathway in chronic myeloid leukemia cell lines
Qian Wang et al.
ONCOTARGET (2017)
The Role of New Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Priyanka A. Pophali et al.
CANCER JOURNAL (2016)
Genomic Classification and Prognosis in Acute Myeloid Leukemia
Elli Papaemmanuil et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Hybrid pyrimidine alkynyls inhibit the clinically resistance related Bcr-AblT315I mutant
Xiaoyun Lu et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2015)
CtBP maintains cancer cell growth and metabolic homeostasis via regulating SIRT4
L. Wang et al.
CELL DEATH & DISEASE (2015)
Homoharringtonine contributes to imatinib sensitivity by blocking the EphB4/RhoA pathway in chronic myeloid leukemia cell lines
Bin-Tao Huang et al.
MEDICAL ONCOLOGY (2014)
Ponatinib: A New Tyrosine Kinase Inhibitor for the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Caitlin L. Shamroe et al.
ANNALS OF PHARMACOTHERAPY (2013)
Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors
Franck E. Nicolini et al.
HAEMATOLOGICA (2013)
Identification of GZD824 as an Orally Bioavailable Inhibitor That Targets Phosphorylated and Nonphosphorylated Breakpoint Cluster Region-Abelson (Bcr-Abl) Kinase and Overcomes Clinically Acquired Mutation-Induced Resistance against Imatinib
Xiaomei Ren et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Design, Synthesis, and Biological Evaluation of 3-(1H-1,2,3-Triazol-1-yl)benzamide Derivatives as Potent Pan Bcr-Abl Inhibitors Including the Threonine315→Isoleucine315 Mutant
Yupeng Li et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: A review
Xin An et al.
LEUKEMIA RESEARCH (2010)
Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia
Ellen Weisberg et al.
NATURE REVIEWS CANCER (2007)
分享论文
